Patents Assigned to CLEVELAND HEARTLAB, INC.
-
Patent number: 11940452Abstract: Provided herein are compositions, systems, and methods for extracting and detecting at least one HDL-associated protein (e.g., ApoA1) from a sample (e.g., plasma or serum sample). In certain embodiments, a strong organic acid and hydrophilic organic solvent are mixed with the sample; after centrifugation, the supernatant is transferred to a second container where it is mixed with a non-polar organic solvent; after centrifugation, the lower aqueous layer is transferred to a third container; and then at least a portion of the transferred aqueous layer is subjected to a detection assay such that at least one HDL-associated protein is detected.Type: GrantFiled: October 29, 2019Date of Patent: March 26, 2024Assignee: Cleveland Heartlab, Inc.Inventors: Cory Bystrom, Timothy Collier
-
Publication number: 20220155302Abstract: Provided herein are methods, systems, and compositions for Lp-PLA2 detection assays that employ amounts of detergent to liberate all or nearly all of the Lp-PLA2 molecules from associated lipoprotein particles. In this regard, the true Lp-PLA2 concentration can be detected in a sample, which correlates better with known Lp-PLA2 activity assays.Type: ApplicationFiled: January 31, 2022Publication date: May 19, 2022Applicant: CLEVELAND HEARTLAB, INC.Inventors: Celalettin Topbas, Cory Bystrom
-
Patent number: 11237167Abstract: Provided herein are methods, systems, and compositions for Lp-PLA2 detection assays that employ amounts of detergent to liberate all or nearly all of the Lp-PLA2 molecules from associated lipoprotein particles. In this regard, the true Lp-PLA2 concentration can be detected in a sample, which correlates better with known Lp-PLA2 activity assays.Type: GrantFiled: January 18, 2018Date of Patent: February 1, 2022Assignee: Cleveland Heartlab, Inc.Inventors: Celalettin Topbas, Cory Bystrom
-
Publication number: 20210373038Abstract: The present invention provides methods, kits, and compositions for purifying HDL molecules from a sample (e.g., blood sample) using HDL tagging molecules comprising an HDL lipophilic core binding peptide (e.g., portion of ApoA1) and an affinity tag. The present invention also provides methods, kits, and compositions for detecting non-fragmented ApoA1 with mass spectrometry. The present invention further provides methods, kits, and compositions for tagging HDL molecules in a sample with detectably labeled ApoA1 molecules such that the ratio of detectably labeled ApoA1 molecules to native ApoA1 proteins may be determined.Type: ApplicationFiled: July 2, 2021Publication date: December 2, 2021Applicant: CLEVELAND HEARTLAB, INC.Inventors: Timothy Collier, Cory Bystrom, Angela Higgins
-
Patent number: 11061039Abstract: The present invention provides methods, kits, and compositions for purifying HDL molecules from a sample (e.g., blood sample) using HDL tagging molecules comprising an HDL lipophilic core binding peptide (e.g., portion of ApoA1) and an affinity tag. The present invention also provides methods, kits, and compositions for detecting non-fragmented ApoA1 with mass spectrometry. The present invention further provides methods, kits, and compositions for tagging HDL molecules in a sample with detectably labeled ApoA1 molecules such that the ratio of detectably labeled ApoA1 molecules to native ApoA1 proteins may be determined.Type: GrantFiled: December 4, 2018Date of Patent: July 13, 2021Assignee: Cleveland Heartlab, Inc.Inventors: Timothy Collier, Cory Bystrom, Angela Higgins
-
Publication number: 20210132090Abstract: Provided herein are methods, systems, and compositions for detecting one or more HDL-associated proteins (e.g., ApoC3; ApoC3 and ApoA1; ApoC3 and SAA1/2; or proteins in Biomarker Panels 1-30) in a sample from a subject with, or suspected of having, cardiovascular disease (CVD) or other HDL related disease. In certain embodiments, such methods, systems, and compositions are used to determine the approximate risk of CVD (or other disease) for a subject, and/or the approximate cholesterol efflux capacity (CEC) of a sample.Type: ApplicationFiled: January 7, 2021Publication date: May 6, 2021Applicant: Cleveland Heartlab, Inc.Inventors: Cory Bystrom, Timothy Collier
-
Patent number: 10921331Abstract: Provided herein are methods, systems, and compositions for detecting one or more HDL-associated proteins (e.g., ApoC3; ApoC3 and ApoA1; ApoC3 and SAA1/2; or proteins in Biomarker Panels 1-30) in a sample from a subject with, or suspected of having, cardiovascular disease (CVD) or other HDL related disease. In certain embodiments, such methods, systems, and compositions are used to determine the approximate risk of CVD (or other disease) for a subject, and/or the approximate cholesterol efflux capacity (CEC) of a sample.Type: GrantFiled: July 21, 2017Date of Patent: February 16, 2021Assignee: Cleveland Heartlab, Inc.Inventors: Cory Bystrom, Timothy Collier
-
Publication number: 20200116744Abstract: Provided herein are compositions, systems, and methods for extracting and detecting at least one HDL-associated protein (e.g., ApoA1) from a sample (e.g., plasma or serum sample). In certain embodiments, a strong organic acid and hydrophilic organic solvent are mixed with the sample; after centrifugation, the supernatant is transferred to a second container where it is mixed with a non-polar organic solvent; after centrifugation, the lower aqueous layer is transferred to a third container; and then at least a portion of the transferred aqueous layer is subjected to a detection assay such that at least one HDL-associated protein is detected.Type: ApplicationFiled: October 29, 2019Publication date: April 16, 2020Applicant: CLEVELAND HEARTLAB, INC.Inventors: Cory Bystrom, Timothy Collier
-
Patent number: 10466260Abstract: Provided herein are compositions, systems, and methods for extracting and detecting at least one HDL-associated protein (e.g., ApoA1) from a sample (e.g., plasma or serum sample). In certain embodiments, a strong organic acid and hydrophilic organic solvent are mixed with the sample; after centrifugation, the supernatant is transferred to a second container where it is mixed with a non-polar organic solvent; after centrifugation, the lower aqueous layer is transferred to a third container; and then at least a portion of the transferred aqueous layer is subjected to a detection assay such that at least one HDL-associated protein is detected.Type: GrantFiled: October 20, 2017Date of Patent: November 5, 2019Assignee: Cleveland Heartlab, Inc.Inventors: Cory Bystrom, Timothy Collier
-
Patent number: 9810702Abstract: Provided herein are compositions, systems, and methods for extracting and detecting at least one HDL-associated protein (e.g., ApoA1) from a sample (e.g., plasma or serum sample). In certain embodiments, a strong organic acid and hydrophilic organic solvent are mixed with the sample; after centrifugation, the supernatant is transferred to a second container where it is mixed with a non-polar organic solvent; after centrifugation, the lower aqueous layer is transferred to a third container; and then at least a portion of the transferred aqueous layer is subjected to a detection assay such that at least one HDL-associated protein is detected.Type: GrantFiled: September 18, 2015Date of Patent: November 7, 2017Assignee: THE CLEVELAND HEARTLAB, INC.Inventors: Cory Bystrom, Timothy Collier
-
Publication number: 20150376704Abstract: The disclosed methods, assays and kits identify biomarkers, particularly miRNA and/or protein biomarkers, for assessing the cardiovascular health of a human. In certain embodiments, methods, assays and kits, circulating miRNA and/or protein biomarkers are identified for assessing the cardiovascular health of a human.Type: ApplicationFiled: July 1, 2015Publication date: December 31, 2015Applicant: CLEVELAND HEARTLAB, INC.Inventors: Doug Harrington, Evangelos Hytopoulos, Bruce Phelps